Ardent Health, Inc. (ARDT) Raises 2026 Adjusted EBITDA Guidance to $500–535M
Ardent Health (ARDT) raised its 2026 adjusted EBITDA guidance to $500–535M from $485–535M, while maintaining revenue guidance at $6,400–6,700M. The board also approved a $25M increase to the share repurchase program. The update follows the company's third-quarter results, but specific quarterly figures were not provided.
How this was made

The 30-second read
Why it matters
The raised EBITDA range and larger buyback program provide a fresh positive catalyst for the stock.
Market read
Guidance upgrades typically move the stock higher; traders may adjust positions accordingly.
What to watch
Potential headwinds from payer negotiations or regulatory changes not discussed.
Background
Ardent Health (ticker ARDT) issued a press release updating its 2026 financial outlook.
Ticker impact
Ardent Health raised its 2026 adjusted EBITDA guidance to $500‑535M and increased its share repurchase program by $25M.
likely upside as investors price in higher EBITDA and increased buyback support.
The new guidance is material and the first report, providing fresh positive catalyst.
Market effects
May lift sentiment for the broader healthcare services sector.
US healthcare stocks could see modest gains.
Limited to US markets; no global ripple.
Counterpoint
If the guidance increase is already priced in, the stock could face short‑term profit taking.
Key entities
- companyArdent Health, Inc.
US‑listed healthcare services provider.

